摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3,4,5-trimethoxybenzyl)acetamide

中文名称
——
中文别名
——
英文名称
N-(3,4,5-trimethoxybenzyl)acetamide
英文别名
N-(3,4,5-trimethoxybenzyl) acetamide;N-(3,4,5-trimethoxybenzyl)-acetamide;N-[(3,4,5-trimethoxyphenyl)methyl]acetamide
N-(3,4,5-trimethoxybenzyl)acetamide化学式
CAS
——
化学式
C12H17NO4
mdl
MFCD15570260
分子量
239.271
InChiKey
ZGUZLVSAOBXQNC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    56.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    乙酰胺3,4,5-三甲氧基苯甲醛dicobalt octacarbonyl氢气三(对甲苯基)锑 作用下, 以 四氢呋喃 为溶剂, 120.0 ℃ 、4.48 MPa 条件下, 反应 24.0h, 以80%的产率得到N-(3,4,5-trimethoxybenzyl)acetamide
    参考文献:
    名称:
    One-pot stibine modified Co2(CO)8 catalyzed reductive N-alkylation of primary amides with carbonyl compounds
    摘要:
    A one-pot stibine modified Co-2(CO)(8) homogeneous catalytic reductive N-alkylation of primary amides using aldehydes/ketones as alkylating agents, is reported. Good to excellent yields of a wide range of secondary amides are obtained (up to 97%) under relative mild conditions. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2012.01.038
点击查看最新优质反应信息

文献信息

  • [EN] 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS<br/>[FR] DERIVES DE 2-(6-AMINO-PYRIDINE-3-YL)-2-HYDROXYETHYLAMINE UTILISES COMME AGONISTES DES RECEPTEURS BETA 2-ADRENERGIQUES
    申请人:PFIZER LTD
    公开号:WO2004108676A1
    公开(公告)日:2004-12-16
    The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    该发明涉及公式(1)的化合物,以及用于制备、用于制备的中间体、含有和用途的过程。根据本发明的化合物在许多疾病、紊乱和状况中特别有用,特别是在炎症性、过敏性和呼吸系统疾病、紊乱和状况中。
  • [EN] COMPOUNDS HAVING BETA-AGONIST ACTIVITY<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE BETA-AGONISTE
    申请人:PFIZER LTD
    公开号:WO2005092841A1
    公开(公告)日:2005-10-06
    The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    本发明涉及化合物的公式(1)以及用于制备、制备中间体、含有和使用这些衍生物的过程。根据本发明的化合物在许多疾病、紊乱和情况中有用,特别是炎症性、过敏性和呼吸道疾病、紊乱和情况。
  • Inhibitors of Serine Proteases
    申请人:Farmer Luc
    公开号:US20100272681A1
    公开(公告)日:2010-10-28
    The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    本发明涉及抑制丝氨酸蛋白酶活性的化合物,特别是针对丙型肝炎病毒NS3-NS4A蛋白酶的活性。这些化合物通过干扰丙型肝炎病毒的生命周期来发挥作用,并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物,无论是用于体外使用还是用于治疗患有HCV感染的患者。本发明还涉及通过给患者注射包含本发明化合物的组合物来治疗HCV感染的方法。
  • Substituted pyrazoles as p38 kinase inhibitors
    申请人:Naraian S. Ashok
    公开号:US20070078146A1
    公开(公告)日:2007-04-05
    A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.
    描述了一类吡唑衍生物,用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义,其中R1、R2、R3和R4如规范中所述。
  • [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof
    申请人:Masuda Akira
    公开号:US20070010515A1
    公开(公告)日:2007-01-11
    Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.
    这是一种通式为(1)的[1,2,4]三唑并[1,5-a]嘧啶衍生物的小说,其中(1)是其前药或其药学上可接受的盐,具有抗原呈递抑制活性,可用作预防和/或治疗器官/骨髓移植、自身免疫性疾病、过敏性疾病和/或炎症性疾病的免疫排斥和/或移植物抗宿主反应的预防和/或治疗剂,同时也可用作抗癌药物或用于移植器官/移植骨髓的免疫耐受诱导剂。
查看更多